Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O)

Breast Cancer Clinical Trial

Official title:

Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05403177
• Other study ID #: MOHCCN-O
• Status: Recruiting
• Start date: June 23, 2022
• Est. completion date: October 2026

Study information

• Verified date: June 2023
• Source: University Health Network, Toronto
• Contact: PM2C Central Office
• Phone: 416.946.4501
• Email: MOHCCN[@]uhn.ca
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The Marathon of Hope Cancer Centres Network (MOHCCN) is a national network of cancer centres that pursue collaborative cancer research in precision medicine (an emerging approach for disease treatment and prevention that considers individual variability in DNA, environment and lifestyle) to accelerate the discovery of innovations and improve the health outcomes for cancer patients

Description:

The purpose of this study is to use evolving technologies such as genomics and artificial intelligence to study cancer so that the right treatment can be given to the right patient, at the right time. Approximately 15,000 participants will take part in the greater MOHCCN study across Canada in the first 5 years, and ultimately the goal is to enroll up to 100,000 over next 10 years.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 500
• Est. completion date: October 2026
• Est. primary completion date: October 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients with histological and cytological confirmation of blood or solid tumor malignancies.

2. All patients must be able to satisfy the required minimum data elements for the 15k

gold standard cohort through:

• existing data that satisfies the minimal requirements of a gold standard case, AND/OR
• previously collected and sufficient biospecimens (tumor and/or blood samples) for whole-genome and transcriptome sequencing and immunophenotype characterization, AND/OR
• new blood collection and/or tumor biopsy

3. Agrees to share anonymized clinical and genomic data. Exclusion Criteria: None.

Related Conditions & MeSH terms

• Breast Cancer
• Colorectal Cancer
• Head and Neck Cancer
• Kidney Cancer
• Kidney Neoplasms
• Leukemia
• Lung Cancer
• Lymphoma
• Melanoma
• Ovarian Neoplasms
• Ovary Cancer
• Pancreas Cancer
• Pancreatic Neoplasms
• Prostate Cancer
• Solid Tumor

Locations

Country	Name	City	State
Canada	Princess Margaret Cancer Centre	Toronto	Ontario

Sponsors (4)

Lead Sponsor	Collaborator
University Health Network, Toronto	Ontario Institute for Cancer Research, Princess Margaret Hospital, Canada, Terry Fox Research Institute

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of patients included in a pan-Canadian cohort with comprehensive clinical and genomic data		5 years
Secondary	Development of standard practices to create a unique shareable dataset of molecular, imaging, clinical and health outcome information on Canadian cancer cases		5 years
Secondary	Clinical effectiveness and cost-effectiveness of precision cancer medicine to advance clinical implementation and reimbursement decisions	Health technology assessment tools will be used to evaluate the real-world value of precision medicine	5 years
Secondary	Development and collection of patient-reported outcomes to enhance patient-centeredness in precision cancer medicine	Health technology assessment tools will be used to evaluate the real-world value of precision medicine	5 years